Kamala Harris’ stance on Big Pharma: 5 things to know

Five things to understand about Ms. Harris past declarations and strategies related to the pharmaceutical industry:.

Early on in her presidential project, Ms. Harris tweeted: “Big pharmaceutical business have unleashed an opioid crisis from the California coast to the mountains of West Virginia. At last, we need to call drug addiction what it is: a nationwide public health emergency situation.”.

More short articles on pharmacy: CVS HealthHub rollout resumesMerck bets on one-shot vaccineVirginia pharmacy school files match against accreditation firm, calls process bizarrely contradictory and Kafkaesque.

Throughout an October Democratic governmental argument, Ms. Harris called huge pharmaceutical business included in the opioid crisis “high-level dope dealers.”.

In Feb. 2019, Ms. Harris presented a costs to avoid large drug rate hikes, called the FLAT Prices Act, which would reduce drugmakers monopoly periods and bring generic drugs to the market quicker. “No one must be forced to forgo lifesaving medication due to the fact that they cant afford it. Its unconscionable that drug companies jack up rates on medications when there are no budget-friendly options for clients to rely on. This is an abuse of our patent system, and it needs to stop,” Ms. Harris stated..

Ms. Harris launched a strategy that consisted of utilizing a global rate index to lower pharmaceutical expenses in the U.S when she was a 2020 candidate for president. The strategy would permit the U.S. government to set lower rates on all prescription drugs and enhance completing options, according to Vox. Her plan would also prevent drug companies from using advertising expenses as tax write-offs.

Joe Biden, the presumptive Democractic nominee for president, named Sen. Kamala Harris of California his vice presidential choice Aug. 11..

In 2016, Ms. Harris filed a lawsuit against Chesterfield, Va.-based drugmaker, Indivior, declaring that it, together with MonoSolRX, an Indiana-based pharmaceutical film technology business, participated in a plan to block competition to Suboxone, an opioid addiction treatment.

Maia Anderson –
Wednesday, August 12th, 2020
Print|Email.

When she was a 2020 candidate for president, Ms. Harris released a strategy that included utilizing an international cost index to lower pharmaceutical expenses in the U.S. The plan would enable the U.S. government to set lower costs on all prescription drugs and improve completing options, according to Vox. In Feb. 2019, Ms. Harris presented an expense to prevent large drug rate hikes, called the FLAT Prices Act, which would reduce drugmakers monopoly periods and bring generic drugs to the market faster. Its unconscionable that drug business jack up costs on medications when there are no budget-friendly alternatives for clients to turn to.

© Copyright ASC COMMUNICATIONS 2020. Intrigued in LINKING to or REPRINTING this material? View our policies by click on this link.